

# Câncer de Pulmão Não Pequenas Células

## **Carboplatina + Paclitaxel**

Paclitaxel: 200mg/m<sup>2</sup> IV D1  
Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos  
Ref. (1)

## **Vinorelbina + Cisplatina**

Vinorelbina: 25mg/m<sup>2</sup> IV D1 semanal X 16 semanas  
Cisplatina: 50mg/m<sup>2</sup> IV D1 e D8 a cada 28 dias X 4 ciclos  
Ref. (2)

## **Carboplatina + Paclitaxel**

Carboplatina: AUC 6 IV D1  
Paclitaxel: 200 a 225mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (3)

## **OU**

Paclitaxel: 100mg/m<sup>2</sup> IV D1 SEMANAL  
Carboplatina: AUC 6 IV D1 a cada 28 dias  
Ref. (4)

## **Carboplatina + Paclitaxel+ Bevacizumabe**

Paclitaxel: 200mg/m<sup>2</sup> IV D1  
Carboplatina: AUC 6 IV D1  
Bevacizumabe: 15mg/kg IV D1 a cada 21 dias  
Ref. (3)

**Cisplatina + Paclitaxel**

Cisplatina: 80mg/m<sup>2</sup> IV D1  
Paclitaxel: 175mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (5)

**Docetaxel + Carboplatina**

Docetaxel: 75mg/m<sup>2</sup> IV D1  
Carboplatina: AUC 6 IV D1 a cada 21 dias  
Ref. (6)

**Docetaxel + Cisplatina**

Docetaxel: 75mg/m<sup>2</sup> IV D1  
Cisplatina: 75mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (6, 7)

**Docetaxel + Gencitabina**

Docetaxel: 100mg/m<sup>2</sup> IV D8  
Gencitabina: 1100mg/m<sup>2</sup> IV D1 e D8  
G-CSF: 300mcg SC D9 a D15 a cada 21 dias  
Ref. (8)

**Cisplatina + Gencitabina**

Cisplatina: 100mg/m<sup>2</sup> IV D1  
Gencitabina: 1000mg/m<sup>2</sup> IV D1, D8 e D15 a cada  
28 dias Ref. (9)

**Carboplatina + Gencitabina**

Carboplatina: AUC 5 IV D1  
Gencitabina: 1000mg/m<sup>2</sup> IV D1, D8 e D15 a cada  
28 dias Ref. (10)

**Gencitabina + Vinorelbina**

Gencitabina: 1200mg/m<sup>2</sup> IV D1 e D8  
Vinorelbina: 30mg/m<sup>2</sup> IV D1 e D8 a cada 21 dias  
Ref. (11)

### **Vinorelbina + Carboplatina**

Vinorelbina: 25mg/m<sup>2</sup> IV D1 e D8  
Carboplatina: AUC 6 IV D1 a cada 28 dias  
Ref. (12)

### **Pemetrexede + Cisplatina**

Pemetrexede: 500mg/m<sup>2</sup> IV D1  
Cisplatina: 75mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (13)

### **Pemetrexede + Carboplatina**

Pemetrexede: 500mg/m<sup>2</sup> IV D1  
Carboplatina: AUC5 IV D1 a cada 21 dias Ref. (14)

### **EP**

Etoposide: 120mg/m<sup>2</sup> IV D1-D3  
Cisplatina: 60mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (15)

### **Paclitaxel**

Paclitaxel: 225mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (16)

### **OU**

Paclitaxel: 80-100mg/m<sup>2</sup> IV D1-D8-D15 a cada 21 dias  
Ref. (17)

### **Docetaxel**

Docetaxel: 75mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (18)

### **OU**

Docetaxel: 35mg/m<sup>2</sup> IV D1, D8 e D15 a cada 28 dias  
Ref. (19)

### **Pemetrexede**

Pemetrexede: 500mg/m<sup>2</sup> IV D1 a cada 21 dias  
Ref. (20)

### **Gencitabina**

Gencitabina: 1000mg/m<sup>2</sup> IV D1, D8, D15 a cada  
28 dias Ref. (21)

### **Vinorelbina**

Vinorelbina: 25mg/m<sup>2</sup> IV D1 Semanal  
Ref. (22)

### **Gefitinibe**

Gefitinibe: 250mg/m<sup>2</sup> VO Contínuo  
Ref. (23)

### **Erlotinibe**

Erlotinibe: 150mg/dia VO Contínuo Ref. (24)

### **Bevacizumabe+ Cisplatina+ Gencitabina**

Bevacizumabe: 7,5mg/kg IV D1  
Cisplatina: 80mg/m<sup>2</sup> IV D1  
Gencitabina: 1200mg/m<sup>2</sup> IV D1 e D8  
a cada 21 dias  
Ref. (25)

### **Cetuximabe+ Cisplatina + Vinorelbina**

Cetuximabe: 400mg/m<sup>2</sup> IV D1 ATAQUE  
Cetuximabe: 250mg/m<sup>2</sup> IV Semanal  
Cisplatina: 80mg/m<sup>2</sup> IV D1  
Vinorelbina: 25mg/m<sup>2</sup> IV D1 e D8 a cada 21 dias  
Ref. (26)

### **Vinblastina + Cisplatina**

Vinblastina:  $4\text{mg}/\text{m}^2$  D1, D8, D15 e D28. Após o D43, repetir o ciclo a cada 2 semanas até a última administração de cisplatina.

Cisplatina:  $80\text{mg}/\text{m}^2$  IV D1

Repetir a cisplatina cada 21 dias por 4 ciclos (D1, D22, D43 e D64).

Ref. (27)

### **Etoposide + Cisplatina**

Etoposide:  $100\text{mg}/\text{m}^2$  IV D1 ao D3 com cada administração de cisplatina.

Cisplatina:  $80\text{mg}/\text{m}^2$  IV D1

a cada 28 dias no total de 4 ciclos

Ref. (28)

### **MIP**

Mitomicina:  $6\text{mg}/\text{m}^2$  IV D1

Ifosfamida:  $3000\text{mg}/\text{m}^2$  IV D1

Cisplatina:  $50\text{mg}/\text{m}^2$  IV D1 a cada 21 dias por 3 ciclos

Ref. (29)

### **MIP(2)**

Mitomicina:  $6\text{mg}/\text{m}^2$  IV D1

Ifosfamida:  $1500\text{mg}/\text{m}^2$  IV D1 a D3

Cisplatina:  $30\text{mg}/\text{m}^2$  IV D1 a D3 a cada 21 dias por 2 ciclos

Ref. (30)

### **Cisplatina + Irinotecano**

Cisplatina:  $80\text{mg}/\text{m}^2$  IV D1

Irinotecano:  $60\text{mg}/\text{m}^2$  IV D1, D8 e D15 a cada 28 dias

Ref. (31)

## **Carboplatina + Paclitaxel**

Carboplatina: AUC:6      IV      D1

Paclitaxel: 90 mg/m<sup>2</sup>      IV      D1, D8 e D15 a cada 28 dias

Ref. (32)

1. Strauss, G.M., *et al.* Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol*, 2008. 26(31): p. 5043-51.
2. Winton, T., *et al.* Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med*, 2005. 352(25): p. 2589-97.
3. Sandler, A., *et al.* Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med*, 2006. 355(24): p. 2542-50.
4. Belani, C.P., *et al.* Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. *J Clin Oncol*, 2008. 26(3): p. 468-73.
5. Giaccone, G., *et al.* Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *J Clin Oncol*, 1998. 16(6): p. 2133-41.
6. Fossella, F., *et al.* Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol*, 2003. 21(16): p. 3016-24.
7. Belani, C.P., *et al.* Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial. *Clin Lung Cancer*, 1999. 1(2): p. 144-50.
8. Georgoulas, V., *et al.* Platinum-based and non-platinum-

- based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. *Lancet*, 2001. 357(9267): p. 1478-84.
9. Abratt, R.P., *et al.* Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. *J Clin Oncol*, 1997. 15(2): p. 744-9.
  10. Langer, C.J., *et al.* Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. *Semin Oncol*, 1999. 26(1 Suppl 4): p. 12-8.
  11. Frasci, G., *et al.* Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. *J Clin Oncol*, 2000. 18(13): p. 2529-36.
  12. Cremonesi, M., *et al.* Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study. *Oncology*, 2003. 64(2): p. 97-101.
  13. Scagliotti, G.V., *et al.* Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol*, 2008. 26(21): p. 3543-51.
  14. Scagliotti, G.V., Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. *Semin Oncol*, 2005. 32(2 Suppl 2): p. S5-8.
  15. Longeval, E. and J. Klastersky, Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium). *Cancer*, 1982. 50(12): p. 2751-6.
  16. Lilenbaum, R.C., *et al.* Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol*, 2005. 23(1): p. 190-6.
  17. Tester, W.J., *et al.* Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. *Cancer*, 1997. 79(4): p. 724-9.
  18. Miller, V.A. and M.G. Kris, Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment

of patients with advanced non-small cell lung cancer. *Semin Oncol*, 2000. 27(2 Suppl 3): p. 3-10.

19. Hainsworth, J.D., *et al.* Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. *Cancer*, 2000. 89(2): p. 328-33.
20. Hanna, N., *et al.* Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol*, 2004. 22(9): p. 1589-97.
21. Manegold, C., *et al.* Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. *Ann Oncol*, 1997. 8(6): p. 525-9.
22. Furuse, K., *et al.* Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. *Ann Oncol*, 1996. 7(8): p. 815-20.
23. Herbst, R.S., Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. *Semin Oncol*, 2003. 30(1 Suppl 1): p. 30-8.
24. Rosell, R., *et al.* Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med*, 2009. 361(10): p. 958-67.
25. Reck, M., *et al.* Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. *J Clin Oncol*, 2009. 27(8): p. 1227-34.
26. Pirker, R., *et al.* Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet*, 2009. 373(9674): p. 1525-31.
27. Arriagada R, Bergman B, Dunant A, *et al.* The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-



based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *N Engl J Med* 2004;350:351-60.

- 28.** Arriagada R, Bergman B, Dunant A, *et al.* The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *N Engl J Med* 2004;350:351-60.
- 29.** Rosell R, *et al.* A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery With Surgery Alone In Patients With Non-Small-Cell Lung Cancer. *N Engl Med* 1994;330:153-8.
- 30.** Depierre A., *et al.* Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer. *J Clin Oncol* 2002;20:247-251.
- 31.** DeVore RF, *et al.* Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol* 1999;17:2710-20.
- 32.** Quoix E. A., Oster J., Westeel V., *et al.* Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 28:18s, 2010 (suppl; abstr 2).